Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009

Current Oncology

N. Bouganim¹  A. Mamo³  D.W. Wasserman²  P. Metrakos¹  G. Batist³  M. Hassanain²  P. Kavan³  P. Chaudhury² 

[1] Royal victoria hospital;Royal Victoria Hospital;McGill university

关键词: Bevacizumab;    colorectal cancer;    efficacy;    safety;   

DOI  :  

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

BackgroundBefore its regulatory approval in Canada, bevacizumab to treat patients with colorectal cancer (crc) was accessed through the Bevacizumab Expanded Access Trial and a special-access program at the Jewish General Hospital. We retrospectively evaluated patient outcomes in that large cohort. Methods All patients ( n= 196) had metastatic crc, were bevacizumab-naïve, and received bevacizumab in combination with chemotherapy at the Jewish General Hospital between 2004 and 2009. We collected patient demographics and clinical characteristics; relevant medical history, disease stage and tumour pathology at diagnosis; type, duration, and line of therapy; grades 3 and 4 adverse events (aes), time to disease progression (ttp), and overall survival (os) from diagnosis. Results Median follow-up was 36.0 months. Median ttp was 8.0 months [95% confidence interval (ci): 7.0 to 9.0 months). Median os was 41.0 months (95% ci: 36.0 to 47.0 months). Of the 40 grades 3 and 4 bevacizumabrelated aes experienced by 38 patients (19.4%), the most common were thrombocytopenia ( n= 17), deep-vein thrombosis ( n= 6), pulmonary embolism ( n= 4), and hypertension ( n= 3). Conclusions In an expanded access setting, our data reflect the efficacy and safety of bevacizumab-based therapy in the controlled post-registration clinical trial setting.

【 授权许可】

Unknown